



August 17, 2018

Federal Communications Commission
445 12th Street SW
Washington, DC 20554

Subject: Limited Agency Agreement
Laerdal Medical AS
FCC ID: QHQ20-10494

To Whom It May Concern:

We, Laerdal Medical AS, hereby authorized Intertek Testing Services to act as our Agent for the purpose of preparing application for FCC ID number QHQ20-10494 under all applicable parts of the FCC rules and regulations.

The effective date of this limited agency agreement is August 17, 2018. The Limited Agency Agreement expires on August 17, 2019, unless sooner terminated or extended by written notice to Intertek Testing Services and the Federal Communications Commission.

This is to advise that we are in full compliance with the Anti-Drug Abuse Act. The applicant is not subject to a denial of federal benefits pursuant to Section 5301 of the Anti-Drug Act of 1988, 21 U.S.C. 862, and no party to the application is subject to a denial of federal benefits pursuant to that section.

If you have any questions or comments, please do not hesitate to contact me.

Sincerely,

Mari Kaada

Corporate Regulatory Affairs Manager

Laerdal Medical AS

Mail address
Laerdal Medical AS
P.O. Box 377
4002 Stavanger,
Norway

E-mail and Website
post@laerdal.no
www.laerdal.com

Office address
Tanke Svilandsgate 30
4007, Stavanger,
Norway

Telephone
+47 51 51 17 00
Telefax
+47 51 52 35 57

Org.no. 979 484 488